INVESTORFORUMOctober 17-18, 2018The Westin St. Francis • San Francisco, CA

The BIO Investor Forum is an international biotech investor conference focused on investment trends and opportunities in life sciences, with unbiased emphasis on venture-stage growth and emerging public companies as well as those poised to join the growth “watch list” in 2019.

BIO Investor Forum features include:• Public and venture-stage company presentations.

• Expert-led workshops on the latest market and investment opportunities with emphasis on drug and technology development.

• BIO One-on-One Partnering™ meetings.

• Premier opportunity to network with industry executives and investors focused exclusively on life sciences.

Target Audience• Private equity and public investors, research analysts,

and industry executives focused on investment and business development opportunities in the life sciences.

Why Investors Attend• Hear from and meet with executives at the top life

sciences growth companies.

• Evaluate fresh investment opportunities including compatible, complementary and competitive companies.

• Benefit from candid panel discussions with leading clinical experts and investigators with insights on pipeline research and clinical practice.

• Get a ‘big picture’ overview of the industry and the issues affecting product innovation, capitalization, and commercialization.

Why Companies Attend• Meet one-on-one with new and current investors,

analysts, and partnering companies.

• Get the pulse on the latest life sciences investment trends from sophisticated investment and company executives.

• Showcase your company story in presentations to qualified investors.

• Network with peers, investors and potential partners.

Accelerate Discovery. Amplify Returns.

168Presenting Companies

1,000+Attendees

2,760Partnering

Meetings Scheduled

369Partnering Companies

#BIF18 bio.org/investorforum

INVESTORFORUM

October 17-18, 2018The Westin St. Francis • San Francisco, CA

Accelerate Discovery. Amplify Returns.

#BIF18 bio.org/investorforum

AUDIENCE DEMOGRAPHICS COMPANIES

BY TYPE

c Biopharmac Investorc Other

42%

33%

25%

COMPANIES BY NUMBER OF EMPLOYEES

c <50 Employeesc 51 to 1,000 Employeesc 1,000* Employees

73%

16%

11%

COMPANIES BY REGION

c USAc Asia

c Otherc Europe

82%

7%6% 5%

ATTENDEES BY JOB TITLE

c C-levelc Executive/VPc Directorc Otherc Investor

36%

15%10%

28%

11%

“Like being at JPM without the crowds.”“Excellent forum for meeting investors or alliance partners for biotech deals.”

“Good keynotes, receptions and management teams.”“Lots of opportunities to meet investors.”

“The investors were great. I don’t know what similar access I’ll have to such a collection again.”

What Attendees are Saying

2017 BIO Investor Forum: Top Therapeutic Areas for Scheduled Meetings

800

700

600

500

400

300

200

100

0

103 104 107 108 109 109 120 121 121 122 136 137 143 147 161 169 171 176 193

251 274 277 293342

723

Ocular Disease

Diabetes mellitus

Prostate tumor

Advanced solid tumor

Genetic disorder

Multiple m

yeloma

Metabolic disorder

Hematological disease

Immune disorder

Breast tumor

Autoimmune disease

Alzheimers diseasePain

Cardiovascular disease

Gastrointestin

al disease

Leukemia

Dermatological disease

Lymphoma

Rheumatoid arthriti

s

Solid tumor

Neurological disease

Inflammatory disease

Infectious disease

NeoplasmCancer

INVESTORFORUM

Accelerate Discovery. Amplify Returns.Accelerate Discovery. Amplify Returns.

INVESTORFORUM

October 17-18, 2018The Westin St. Francis • San Francisco, CA

2018 BIO INVESTOR FORUM Advisory Committee

Samuel Wu, MD, PhDManaging Director, Acuris Partners

Mahendra G. Shah, PhDManaging Director, Vivo Capital

Asish Xavier, PhDVice President, Venture Investments, Johnson & Johnson Innovation – JJDC, Inc.

Douglas Crawford, PhDPartner, BioInnovation Capital

Mahima Agochiya, PhDBusiness Development & Program Manager, SPARK Translational Research Program, Stanford University

Shelley Chu, MD, PhDPartner, Abingworth

Rajeev Dadoo, PhDPartner, S.R. One, Limited

Sara RadcliffePresident and Chief Executive Officer, California Life Science Association (CLSA)

Sabrina Martucci JohnsonPresident and Chief Executive Officer, Daré Bioscience

Stephen RitochChairman & Chief Executive Officer, Blaise Group International

Alex de Winter, PhDManaging Director, GE Ventures

Vinay Bhaskar, PhDPrincipal, MPM Capital

Komathi StemFounder & Chief Executive Officer, monARC Bionetworks

Margaret KimExecutive Director, Life Sciences, JPMorgan Chase & Co.

Janice BourqueManaging Director, Life Sciences, Hercules Technology Growth Capital

Alice Chen, PhDVice President, Accelerator Life Science Partners

John ChambersPresident and Head of Investment Banking, H.C. Wainwright & Co.

Jennifer LandressSenior Vice President and Chief Operating Officer, Biocom

Carolyn Ng, PhDPrincipal, Vertex Ventures HC

Ravi Kiron, PhDHead, BioPharma External Innovation, EMD Serono

Gini Deshpande, PhDFounder & Chief Executive Officer, NuMedii

Charlotte Hubbert, PhDPartner, Gates Foundation Venture Capital

Tao Huang, PhD, JDVenture Partner, Cenova Capital

#BIF18 bio.org/investorforum